OptumRx Settles $1.86M TCPA Class Action Over Unsolicited Calls
OptumRx, a pharmacy benefits manager owned by UnitedHealth Group, has agreed to pay $1.86 million to settle a class action lawsuit claiming the company bombarded patients with thousands of unsolicited prerecorded calls. Affected consumers have until February 4, 2026 to file claims.
The lawsuit targeted OptumRx's practice of placing prerecorded "clinical adherence" calls to patients without getting their consent first—a clear violation of the Telephone Consumer Protection Act. These weren't just random annoyances. According to settlement documents, the company placed these unauthorized calls to non-customers starting April 20, 2020 and continuing through October 22, 2025.
The TCPA, passed back in 1991, draws a hard line: companies can't use prerecorded messages to contact consumers unless they've obtained express written consent beforehand. The law was designed to protect Americans from the now-epidemic plague of robocalls that frustrate millions daily.
OptumRx's calls were pitched as health-minded—reminders for patients to take their medications as prescribed. The problem wasn't the intent; it was the execution. The company simply didn't have documented consent from the people they were calling.
As one of the nation's largest pharmacy benefits managers, OptumRx operates as a middleman between health insurers, employers, and pharmacies. These companies manage drug benefits, negotiate medication prices, and handle pharmacy services for insurance companies and employers. That role gives them access to patient information and pharmacy records—which is presumably why they thought they could make these adherence calls in the first place.
But having someone's phone number doesn't mean you can call them with prerecorded messages. The TCPA requires explicit opt-in consent, no exceptions.
The settlement received preliminary approval on October 22, 2025, with a final fairness hearing scheduled for March 31, 2026. The agreement resolves TCPA claims covering those unsolicited prerecorded clinical adherence calls made since April 20, 2020. Certain calls were carved out of the settlement: prescription refill reminders, COVID-19 vaccine-related calls, and calls to actual OptumRx customers or account holders.
The $1.86 million fund will compensate class members—patients who received these unwanted calls on an estimated 155,244 unique telephone numbers. Eligible claimants are expected to receive pro rata cash payments between $72 and $135, depending on how many valid claims come in. That's what's left after deductions for administration costs (estimated at $207,750), attorneys' fees (up to $580,410), expenses (up to $40,000), and a service award to the named plaintiff (up to $10,000). Payments will go out approximately 60 days after final court approval.
While $1.86 million sounds like a big number, it reflects the relatively modest individual damages typical in TCPA cases. The law caps damages at $500 to $1,500 per violation. The actual payout to each class member depends on total claims submitted during the claims period.
This settlement carries several important reminders for consumers. First, telemarketing protections don't stop at traditional sales calls—they apply to healthcare companies, insurance-related entities, and pharmacy benefit managers too. Second, consent requirements are strict. A company can't justify prerecorded calls just because they have your number or think the call would be helpful. Written consent must be documented and verifiable.
Robocalls remain a persistent problem across industries, and this is just one of many cases involving unauthorized contact. But class action lawsuits like this one provide recourse when companies violate the TCPA on a large scale, allowing individual consumers to seek compensation without filing separate lawsuits.
If you received unsolicited prerecorded clinical adherence calls from OptumRx on a cell phone or VoIP line between April 20, 2020 and October 22, 2025, and you weren't an OptumRx customer or account holder, you may be eligible for compensation. The deadline to file a claim or opt out is February 4, 2026. Claims can be submitted online at www.OptumRxTCPAClassActionSettlement.com or postmarked by the deadline.
If you're filing, gather whatever information you have about the calls—dates, times, phone numbers they came from. Official settlement notices and claim forms are available at the settlement website. Complete and submit your claim form before February 4, 2026, 11:59 p.m. ET, and keep copies of everything you submit. Make sure you meet the class definition: generally, any non-OptumRx customer who received an unsolicited prerecorded clinical adherence call (excluding COVID-related calls and refill reminders) to their cell phone or VoIP line after April 20, 2020 should qualify.
This OptumRx settlement fits into a broader pattern of TCPA enforcement against healthcare-related companies. In recent years, the Federal Trade Commission, state attorneys general, and private litigants have gone after pharmacy chains, insurance companies, and healthcare providers for making unsolicited robocalls or prerecorded calls without proper authorization.
These cases drive home a simple point: the TCPA applies to all industries. Companies can't dodge the law by claiming their calls serve some health or customer service purpose. The law protects consumer autonomy and the right to be free from unwanted contact.
The settlement still needs final approval at the March 31, 2026 hearing, but it's already one of many ongoing efforts to hold companies accountable for violating consumer protection laws. For OptumRx patients who received these calls, the settlement provides a way to recover at least some compensation. More broadly, it reinforces that consumers have legal protections against unsolicited calls, and companies that ignore those protections can face consequences in class action litigation.
If you believe you were contacted in violation of TCPA regulations, you may have legal options beyond this specific settlement. An attorney who specializes in TCPA cases can help you understand your rights and potential remedies.